Experience with the Enzyme Substitution Therapy in Mucopolysaccharidosis


Authors: A. Hlavatá;  L. Kovács
Authors‘ workplace: 2. Detská klinika LFUK a DFNsP, Bratislava prednosta prof. MUDr. L. Kovács, DrSc., MPH
Published in: Čes-slov Pediat 2006; 61 (10): 593-598.
Category: Case Report

Overview

The authors describe the important progress in the therapy of hereditary metabolic disorders at the lysosome level and specifically the possibilities of causal therapy in some of them. They analyze in detail their longest practical experience with causal therapy of mucopolysaccharidosis type I (MPS I). A female patient with neuropathic form of MPS I has been treated since her ten years of age for three years with the enzyme substitution therapy with laronidase (preparation Aldurazyme). Effects of this therapy have been regularly evaluated by objective tests in the course of treatment. In spite of positive results of these tests a relatively significant somatic stigmatization is still present. The self-service of the patient is the most prominent feature of improvement.

Key words:
lysosomal diseases, mucopolysaccharidosis type I and type VI, Gaucher diseases, Fabry disease, Pompe disease, enzyme substitution therapy


Labels
Neonatology Paediatrics General practitioner for children and adolescents
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account